- Home
- DHAI vs AXDX Comparison
DHAI vs AXDX Comparison
Compare DHAI & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- AXDX
- Stock Information
- Founded
- DHAI 2007
- AXDX 1982
- Country
- DHAI United States
- AXDX United States
- Employees
- DHAI N/A
- AXDX N/A
- Industry
- DHAI
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- DHAI
- AXDX Industrials
- Exchange
- DHAI NYSE
- AXDX Nasdaq
- Market Cap
- DHAI 55.5M
- AXDX 44.5M
- IPO Year
- DHAI N/A
- AXDX 1996
- Fundamental
- Price
- DHAI $0.92
- AXDX $1.88
- Analyst Decision
- DHAI
- AXDX Hold
- Analyst Count
- DHAI 0
- AXDX 1
- Target Price
- DHAI N/A
- AXDX $1.00
- AVG Volume (30 Days)
- DHAI 18.6K
- AXDX 62.8K
- Earning Date
- DHAI 08-19-2024
- AXDX 11-07-2024
- Dividend Yield
- DHAI N/A
- AXDX N/A
- EPS Growth
- DHAI N/A
- AXDX N/A
- EPS
- DHAI N/A
- AXDX N/A
- Revenue
- DHAI $67,615,000.00
- AXDX $11,909,000.00
- Revenue This Year
- DHAI N/A
- AXDX $1.42
- Revenue Next Year
- DHAI N/A
- AXDX $4.09
- P/E Ratio
- DHAI N/A
- AXDX N/A
- Revenue Growth
- DHAI 14.15
- AXDX N/A
- 52 Week Low
- DHAI $0.72
- AXDX $0.73
- 52 Week High
- DHAI $3.67
- AXDX $5.78
- Technical
- Relative Strength Index (RSI)
- DHAI 27.12
- AXDX 46.64
- Support Level
- DHAI $1.00
- AXDX $1.77
- Resistance Level
- DHAI $1.40
- AXDX $2.04
- Average True Range (ATR)
- DHAI 0.12
- AXDX 0.10
- MACD
- DHAI -0.01
- AXDX -0.01
- Stochastic Oscillator
- DHAI 16.00
- AXDX 13.56
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.